Rising India Inc (OTCMKTS:RSII) Is Today's Cannabis Focus

Rising India Inc (OTCMKTS:RSII) has taken the OTC Markets by storm and turned into one of 2017's biggest runners. Shares have risen from $.0003 to highs just above $.02 for gains of over 6,500%. As the company makes its foray into the cannabis space, we're taking a closer look to see if RSII can maintain its momentum.RSII got moving last week after the company signed an LOI with Rising BioSciences, Inc. for a reverse merger in which the capital stockholders of Rising Biosciences Inc will acquire control of Rising India toward immediate execution of a business model with a focus in alternative medical and cannabis pharmaceutical markets. As a result of the merger, Rising India CEO, Jim DiPrima agreed to resign as an officer with the Company making way for the appointment of Robert Weber, who also serves as CEO for PAO Group, listed on the OTC Markets as New Wave Holdings (OTCMKTS:NWAV ).We profiled NWAV earlier this month as another microcap runner. NWAV is similar in that it merged with PAO Group Inc, a physicians practice management company with zero debt and actively developing alternative medicine clinics focused on the proper use of cannabis for treatment of chronic and terminal patients. PAO Group alternative medicine clinics are focused on ‘non-traditional’ patient care solutions. Cannabis will be included in the realm of treatment solutions as well as other alternative solutions such as acupuncture, chiropractic, biofeedback, and other solutions depending upon patient needs. As a result of the transaction, PAO Group Inc founder Robert Weber became CEO of NWAV. Weber recently said:

"I feel we have some very favorable circumstances here. There are a number of opportunities in development and marketing of cannabis pharmaceuticals that are synergistic with our endeavors at PAO Group and beyond. Rising Biosciences plans to capitalize on these opportunities toward an assertive growth plan for shareholders alongside a highly expansive business model."

Rising Biosciences looks to be an interesting play. It's a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. Aside from cancer treatment and pain management, some of the uses for medical marijuana include treatment of conditions such as seizure disorders, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, glaucoma and Crohn's disease.

Rising Biosciences is comprised of a team of chemists, physicians, pharmacists and medical marijuana industry veterans for the development of products in a clinical lab environment. Operations will focus on creating product that can be metabolized by the body more efficiently, and with delivery methods more acceptable than smoking, tinctures and oils available on the market today. Procedures will include consistency in terms of quality and true dosage measures of CBD and/or THC delivery through each product the company develops and manufactures.

Cannabis medical research is certainly the place to be right now for investors judging by the success of OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX). Approximately 24 states have legalized Medical Cannabis use and 8 states have legalized recreational use. In California alone, current revenue estimates for the California cannabis industry are projected to increase to over $6.5 billion in 2020. California medical and recreational industry is projected to reach $6.5 billion in revenue by 2020, up from $2.8 billion in 2015. The nation's legal cannabis industry is expected to climb to $23 billion in 2020, up from $5.7 billion in 2015. The state of Colorado recently reported 2016 revenues of $1.3 billion and tax revenues of $200 million.

Currently trading with a market cap of $6.2 million, RSII is an exciting story among small caps. The recent surge in volume is quite impressive as 53 million shares traded hands on Monday when the float is only 158 million. One third of the float changed hands in a single day. This is a sign that the bullish momentum could just be getting started as more traders are discovering RSII as a play on cannabis research. There's also a good size short in the stock and that will create further upside as the squeeze intensifies.

We will be updating our subscribers as soon as we know more. For the latest updates on RSII, sign up below!

Disclosure: We have no position in any of the securities mentioned and have not been compensated for this article.